A groundbreaking UAE-led research initiative has made significant strides in both medicine and space exploration, opening the door for the first astronaut with diabetes to travel to space.
The innovative ‘Suite Ride’ study, carried out on the International Space Station (ISS), unveiled its findings at New York’s Times Square and was celebrated at the Burjeel Institute for Global Health in NYC.
Led by UAE’s Burjeel Holdings in collaboration with Axiom Space, the mission demonstrated that common diabetes management tools like continuous glucose monitors (CGMs) and insulin pens, widely used on Earth, can operate effectively in space. This development marks a significant step forward for astronauts with diabetes, a condition previously deemed a barrier to space missions.
Stay informed with the latest updates. Follow KT on WhatsApp Channels.
“This goes beyond space exploration. It’s about inspiring people worldwide, showing that a diagnosis doesn’t limit their aspirations for space travel,” stated Gavin D’Elia, Global Head of Pharma, Axiom Space.
Fostering an inclusive space future
During the 18-day Axiom Mission 4, researchers examined how to manage insulin-dependent diabetes in microgravity using a range of remote care tools, including real-time CGMs and insulin pens for dosing.
The study found that these devices maintained accuracy under extreme space conditions, matching Earth-based readings. For the first time, astronauts on the ISS had continuous glucose monitoring validated across multiple methods.
“We launched this study to pioneer space medicine aligned with the UAE’s space goals. Besides paving the way for diabetic astronauts, these findings will also revolutionize healthcare delivery on Earth,” said Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Medical City and Clinical Lead of the Burjeel–Ax-4 Space Health Research.
Revolutionizing healthcare on Earth and beyond
The research’s impact extends beyond the space industry, with potential to enhance healthcare in remote and underserved areas on Earth, such as offshore oil platforms, deep-sea missions, or rural communities.
The UAE-based private healthcare group has now expressed its goal to send the first astronaut with diabetes to space, further solidifying the UAE’s expanding influence in global space and health research.
